miglustat has been researched along with Osteolysis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alonzi, DS; Antonopoulos, A; Butters, TD; Chaidos, A; Danks, L; Dell, A; Dwek, RA; Ersek, A; Freidin, A; Goudevenou, K; Haslam, SM; Hatjiharissi, E; Horwood, NJ; Hu, M; Karadimitris, A; Papaioannou, M; Parry, S; Rahemtulla, A; Roberts, I; Santo, AE; Spanoudakis, E; Twigg, G; Vattakuzhi, Y; Williams, LM; Xu, K | 1 |
1 other study(ies) available for miglustat and Osteolysis
Article | Year |
---|---|
Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.
Topics: 1-Deoxynojirimycin; Animals; Cell Line; CSK Tyrosine-Protein Kinase; Female; Glucosyltransferases; Glycoside Hydrolase Inhibitors; Glycosphingolipids; Insulin-Like Growth Factor I; Membrane Microdomains; Mice; Mice, Knockout; Multiple Myeloma; Osteoclasts; Osteolysis; RANK Ligand; src-Family Kinases; TNF Receptor-Associated Factor 6 | 2015 |